Cladribine as a therapeutic option in multiple sclerosis

There is an unmet need for more potent and convenient drugs in the treatment of patients diagnosed with multiple sclerosis (MS). Among five currently investigated oral drugs with an ongoing or completed phase III program, promising efficacy data for oral cladribine have recently been published. However, benefits need to be weighed against potential risks to define the role of this compound within current treatment regimens. Here we review present data on efficacy of oral cladribine and discuss known and anticipated risks of this drug.

► There is a need in MS therapy for safe, more effective and convenient treatments.
► Cladribine is a drug particularly inducing depletion of T and B lymphocytes.
► Trials with oral cladribinein MS translated into meaningful efficacy results.
► In recent safety analyses no major safety signals could be detected.
► Authorities raised concern about the long-term safety profile of this drug.